-
Reckitt Benckiser LLC v. Aurobindo Pharma Limited et al DC CAFC
- 1:14-cv-01203
- D. Del.
- Judge: Leonard P. Stark
- Filed: 09/17/2014
- Closed: 03/13/2017
- Latest Docket Entry: 10/24/2018
- PACER
- Docket updated daily
1
Plaintiff
2
Defendants
1
Accused
Product
3
Patents-in-Suit
909
Days in
Litigation
-
Reckitt Benckiser LLC v. Aurobindo Pharma Limited et al DC CAFC
- 1:14-cv-01203
- D. Del.
- Judge: Leonard P. Stark
- Filed: 09/17/2014
- Closed: 03/13/2017
- Latest Docket Entry: 10/24/2018
- PACER
- Docket updated daily
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
Aurobindo Pharma Limited
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 30 mg/600 mg, 60 mg/1200 mg OTC dextromethorphan hydrobromide, guaifenesin extended-release tablets | US 6,372,252 B1 | All Asserted Claims |
No infringement
Entry 175
|
| 30 mg/600 mg, 60 mg/1200 mg OTC dextromethorphan hydrobromide, guaifenesin extended-release tablets | US 6,955,821 B2 | All Asserted Claims |
No infringement
Entry 181Entry 175 |
| 30 mg/600 mg, 60 mg/1200 mg OTC dextromethorphan hydrobromide, guaifenesin extended-release tablets | US 7,838,032 B2 | All Asserted Claims |
No infringement
Entry 181Entry 175 |
Aurobindo Pharma USA Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 30 mg/600 mg, 60 mg/1200 mg OTC dextromethorphan hydrobromide, guaifenesin extended-release tablets | US 6,372,252 B1 | All Asserted Claims |
No infringement
Entry 175
|
| 30 mg/600 mg, 60 mg/1200 mg OTC dextromethorphan hydrobromide, guaifenesin extended-release tablets | US 6,955,821 B2 | All Asserted Claims |
No infringement
Entry 181Entry 175 |
| 30 mg/600 mg, 60 mg/1200 mg OTC dextromethorphan hydrobromide, guaifenesin extended-release tablets | US 7,838,032 B2 | All Asserted Claims |
No infringement
Entry 181Entry 175 |
